Sanofi
French pharma leader — Dupixent biologic blockbuster and Warp Speed vaccine contributor; major biologics manufacturing footprint across France, Germany, and US.
- Country
- France
- Revenue
- €41.6B
- Employees
- ~90,000 emp
GMP EU
FDA GMP
Coverage
| CN | EU | IN | US | |
|---|---|---|---|---|
| genome-engineering | ✓ | ✓ | — | ✓ |
| therapeutics-platforms | ✓ | ✓ | ✓ | ✓ |
Regulatorsfdaepamoa-chinaemanmpa
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Biologics | therapeutics-platforms | Low | → |
| Biopharmaceuticals & biomedicines | therapeutics-platforms | Low | → |
| Xenobiology & expanded genetic alphabet (XNA) | genome-engineering | High | → |
Compiled by BIOECON via the bioecon-brief pipeline.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.